https://www.selleckchem.com/pr....oducts/qnz-evp4593.h
ential of HPMC-based SDs to simultaneously overcome the poor dissolution and tabletability properties of this drug. The global incidence of type 2 diabetes mellitus (T2DM) has enthused the development of new antidiabetic targets with low toxicity and long-term stability. In this respect, free fatty acid receptor 1 (FFAR1), which is also recognized as a G protein-coupled receptor 40 (GPR4, is a novel target for the treatment of T2DM. FFAR1/GPR40 has a high level of expression in β-cells of the pancreas, and the requirement of gluco
Like
Comment
Share
